Background: The benefit of 5 years of adjuvant endocrine therapy for women with hormone receptor-positive (HR + ) breast cancer (BC) is beyond discussion. Nevertheless, the risk of recurrence of luminal BC persists for 15 years or more after diagnosis. Consequently, approaches of extended adjuvant therapy have been investigated in large clinical trials, with the ultimate aim of further reducing the risk of recurrence in patients with HR + BC. Methods: A review of recently published trial data is presented to provide a solid basis for discussion. A discussion of the side effects of long-term endocrine treatment, multigenetic tests aiming to identify patients at particular risk, and an outlook for further promising targets are additional aims of this review. Conclusion: Extended adjuvant therapy seems beneficial in reducing distant relapse and contralateral BC for a selected group of patients with HR + BC, particularly if aromatase inhibitors (AIs) are used after initial tamoxifen therapy. However, patients with lower risk of recurrence and initial AI therapy may suffer more from side effects than benefit from extended therapy.
Introduction
Estrogen receptor-positive (ER + ) early breast cancer (EBC) is often considered as a chronic disease. Even if patients remain disease-free during the first 5 years of adjuvant treatment, about twothirds of all breast cancer (BC) deaths and half of the recurrences occur up to 15 years after diagnosis, 1 with a gross average annual risk of recurrence (ROR) of 2% per year. 2, 3 Others even assume that the long-term ROR continues steadily to at least year 20 and affects even patients with T1N0 disease. 4 Thus, it stands to reason that extended adjuvant therapy might be beneficial for a patient's long-term outcome.
Nodal positive (N + ) disease, increased tumor size 5 as well as ER + BC, in comparison with ER-negative BC, 6 seem to be associated with higher risk of late recurrence. Trying to characterize an adequate tool to identify patients at particular risk for recurrence is therefore more than reasonable. However, the potential reduction of late recurrences and deaths must outweigh the burden of toxic side effects as well as higher economic costs for prolonged therapy. 7 Until now, no established standard regimen has been defined.
In this article, we review the most recent trial data with the aim of clarifying the following issues: whether extended endocrine treatment provides substantial beneficial value for all hormone receptor-positive (HR + ) EBC patients or only for a selected group, and whether any predictive factor can be determined to identify those who benefit the most.
Methods
We performed a systematic literature search in the following electronic databases: PubMed, Cochrane Library and Embase. Unpublished data presented at the San Antonio Breast Cancer Symposium (SABCS) in 2016 were obtained from the SABCS homepage (https://www.sabcs. org/Portals/SABCS2016/). The search terms included: extended endocrine therapy, hormone receptor-positive early breast cancer and postmenopausal women. Reported data from longterm studies were also used for this review.
Findings
Aromatase inhibitors (AIs) for 5 years are superior to tamoxifen (TAM) in postmenopausal women with HR + EBC.
A meta-analysis with 31,920 patients published in 2015 compared different adjuvant treatment regimens: 5 years AI versus 5 years TAM; 5 years AI versus 2-3 years TAM followed by AI to year 5; or 5 years of TAM versus 2-3 years TAM followed by AI to year 5. 8 Significantly lower overall recurrence rates in years 0-4 could be demonstrated for 5 years of AI therapy compared with 5 years of TAM therapy [p < 0.00001; years 0-1 rate ratio (RR) 0.64 (0.52-0.78); years 2-4 RR 0.80 (0.68-0.93)]. Distant, local and contralateral recurrence rates were all significantly reduced. A significant reduction of 10-year BC mortality risk could be achieved with 5 years of AI as well [RR 0.89 (0.81-0.97), p = 0.009]. 8 Another essential finding of this meta-analysis is that TAM followed by AI is an advantageous alternative to TAM alone for 5 years. The ROR in years 2-4 [RR 0.56 (0.46-0.67)] and the 10-year BC mortality were significantly lower (8.7 versus 10.1%, p = 0.015) in patients switching to AI than in those remaining on TAM. However, the AI monotherapy remains superior to the sequenced regimen TAM/AI in recurrence rate [ Of the survivors, 91% were followed up 10 years after diagnosis, 77% until year 15. Nevertheless, a longer follow-up period is required to definitely prove side effects of extended TAM intake since it is known that 5 years of TAM therapy produces an absolute 15-year risk for endometrial cancer of about 2-3%, whereas 10 years of TAM intake would mean an additional risk by year 15 of approximately 2%. 3, 9 The aTTom trial, published in 2013 by Gray and colleagues, 10 However, a precise definition of 'breast cancer recurrence', whether locoregional, contralateral or distant recurrence was meant, is missing. A further limitation of the aTTom trial is that the ER status was untested in 4198 of 6953 patients (60%), thus the ER status was estimated to be positive in 80% of those with unknown status.
In comparison, in the ATLAS trial 37% of the women included had an unknown ER + status. Consequently, only patients with ER + BC were included in recurrence and BC mortality rate calculations.
To sum up, endocrine therapy with TAM beyond 5 years leads to significantly longer recurrencefree, disease-free and probably also overall survival (OS) ( Table 1) ; however, as far as the existing data allow us to draw conclusions, an increased incidence of pulmonary embolism and endometrial cancer as well as an increase of endometrial cancer mortality must be balanced against the benefits. Further, whether the limited survival benefits substantially outweigh economic costs and the above-mentioned adverse events (AEs) must be considered. 13 The MA.17 trial primarily included women who were premenopausal at initial diagnosis; a subgroup analysis published in 2012 showed that extended letrozole after 5 years of initial TAM therapy was effective in both pre-and postmenopausal patients (at time of diagnosis). 15 The results of the NSABP B-33 study published in 2008 supported these results. The trial included 1598 postmenopausal women, who had been suffering from clinical T1-3, N0-1, M0, HR + BC and were disease-free after 5 years of adjuvant therapy with TAM. In a 1:1 ratio patients were either assigned to 5 years of further exemestane treatment or to 5 years of placebo. A nonstatistically significant reduction in DFS event of 32%, translating to a 2% absolute improvement in 4-year DFS (89% for placebo versus 91% for exemestane, p = 0.07) and a statistically significant improvement in 4-year recurrence-free survival (RFS; 96 versus 94%, p = 0.004) 16 were observed. At 2 years after study initiation, the published MA.17 trial 17 showed beneficial outcomes for patients with extended AI therapy. At this time, the NSABP B-33 study was unblinded and 344 of the 779 patients of the placebo group (44%) decided to switch to the exemestane group. This might have led to confounded results due to a relatively small control group. Additionally, the lack of significance regarding OS might be explained by the small number of deaths that had occurred. 16 The ABCSG trial 6a included 856 patients with HR + BC, remaining disease-free after 5 years of TAM, who then were randomized to 3 years of AI therapy or to no further treatment. 18 In a subgroup analysis, additional benefit was also shown for patients with both ER + and progesterone-receptor positive (PR+)tumors, who were randomized to extended therapy (HR 0.32, p < 0.001). The most common complications or AEs were hot flushes, asthenia, somnolence and allergy. 19 A limitation of this trial is the nonplacebo-controlled design and the limited patient number.
AI after TAM
Therefore, extended endocrine treatment with AI leads to prolonged RFS, DFS, but does not consistently impact OS (Table 2) .
Recently published data

AI after TAM/AI
Since sequencing TAM and AI is a commonly used adjuvant therapy constellation, 8 the question arises whether extending AI after initial TAM/AI therapy adds further benefit. There are five recently published studies and one ongoing study dealing with this issue. The study designs are summarized in Figure 1 ; the results of the already presented data are shown in Table 3 . It could be demonstrated that extended AI therapy was most beneficial for patients with prior Thus, patients with worse tumor characteristics, such as ⩾pT2, N + and prior chemotherapy, seem to have a greater benefit from extending adjuvant therapy.
The incidence of AEs after 3 years of randomization was higher in patients receiving AI for 6 years, although only grade 1-2 AEs were observed.
In conclusion, Tjan-Heijnen and colleagues did not recommend extended adjuvant therapy to all postmenopausal patients with HR + BC, whereas a selected group of patients seems to benefit. Instead of extending the duration of adjuvant endocrine therapy, they suggest exploring promising new targeting therapies. 22 Limitations of this study were a short follow-up period (median adapted follow up was 4.1 years) as well as the nonplacebo-controlled and nonblinded study design. The study design of the DATA trial did not include patients with initial sequenced TAM/AI or AI monotherapy.
The IDEAL trial is a multicenter phase III trial, which included 1824 women with HR + BC randomized between 2007 and 2011 with the intention to determine the optimal duration of extended adjuvant letrozole therapy. Patients had to complete 5 years of any commonly used endocrine therapy regimens and then subsequently were randomized to extended adjuvant letrozole therapy, either 2.5 years or 5 years. The primary endpoint of this study was DFS. However, it could be shown that the incidence of secondary BC after 5 years of randomization was higher in women with shorter extended adjuvant therapy than in patients with 5 years of additional AI therapy [1.9 versus 0.9%, HR 0.37 (0.18-0.77), p = 0.008].
The safety assessment found a low number of additional AEs in those patients with further 5 years of letrozole therapy. 23 The nonplacebo-controlled study design might be a limitation.
The SOLE study was recently presented at the ASCO annual meeting in June 2017. This phase III trial included 4884 postmenopausal women with HR + , N + early-stage BC with the purpose to investigate the effect of a new therapy concept of letrozole. It was designed to assess the role of continuous versus intermittent letrozole intake. After 5 years of adjuvant endocrine therapy patients were either randomized to 5 years of continuous (n = 2441) or to 5 years of intermittent (n = 2443) letrozole administration whereby 3-month treatment-free intervals must be adhered to. The hypothesis is that intermittent letrozole intake will permit some estrogenic stimulation during the respective pauses. Within this hormonal withdrawal period, residual cancer might be susceptible to letrozole reintroduction, which should translate into a higher DFS, the primary endpoint of this study. 24 This trial confirmed non-inferiority of the intermittent letrozole administration. Pauses in treatment up to 3 months per year could be tolerated, given that the efficacy of the adjuvant treatment does not decrease. Although it might be assumed that a more flexible therapy administration leads to an increase of patient compliance, in both therapy arms 24% of patients discontinued letrozole earlier.
Interestingly, AEs >grade 3 were reported slightly more often in patients with intermittent letrozole intake (43.5 versus 41.6%, no p-value available).
A still ongoing study is the ABCSG 16-SALSA trial. It is designed as a prospective, randomized, multicenter phase III study aiming to assess the efficacy of secondary adjuvant endocrine anastrozole therapy for a further 2 years versus 5 years, after an initial 5 years of endocrine therapy.
The trial includes postmenopausal women with an invasive T1-3, N0 or N+, M0 and HR + BC, with or without previous chemotherapy or radiotherapy.
The primary endpoint of this study is the effect of 2 versus 5 years of additional anastrozole intake on DFS. 27 Results are expected by the end of 2017.
Recently presented data could not confirm advantageous effects of extended adjuvant therapy for all women with ER + BC. Nevertheless, patients with ER + and PR + BC, or patients at higher risk like N + , pT2 or larger tumors or women after (neo)adjuvant chemotherapy, seem to benefit from extending adjuvant therapy with AI.
AI after TAM versus AI after AI
Data show that the two main therapy strategies, AI after TAM versus AI after AI, provide different beneficial impact on DFS.
There is evidence that the regime AI after TAM comes along with a lower HR for DFS events than the one with AI after AI. Placebo-controlled trials, such as MA.17, 17 NSABP B-33 16 and ABCSG 6a, 19 that compare AI after TAM have shown a HR of 0.57-0.68 regarding DFS events.
As soon as the initial endocrine therapy contains AI, a lower benefit, referring to a lower risk reduction of DFS events, can be anticipated when AI therapy is further extended. This statement is based on results of trials investigating the effect of extended AI after initial AI or TAM/AI therapy. The MA.17R, 20 NSABP B-42 21 and the IDEAL trial 23 observed HRs of 0.80-0.88, translating to a lower risk reduction.
A subgroup analysis within the NSABP B-42 trial showed that patients who received initial ET containing TAM had a significant lower HR regarding DFS than those without prior TAM (HR 0.75 versus 0.91). 21, 28 Adverse events under extended treatment An increase in fracture rates and bone density loss in patients with BC caused by AI treatment is well known. The reason is that AI suppresses the conversion of androgens to estrogens, resulting in estrogen depletion. 29 As shown in many trials, adjuvant endocrine therapy compromises bone health and causes osteopenia and even osteoporosis. The prevention of these side effects could be achieved with the additional administration of bisphosphonates or anti-RANK ligand antibodies.
The ABSCG 12 trial compared adjuvant endocrine therapy regime with tamoxifen or anastrozole ± zoledronic acid in premenopausal patients with ER + EBC. The addition of zoledronic acid resulted in an increased DFS. 30 Several studies provided evidence that zoledronic acid reduces incidence of micrometastasis in the bone marrow. 31, 32 To summarize, zoledronic acid journals.sagepub.com/home/tam 687 does not only have antitumor effects in the bone, but also a beneficial impact on DFS. 30 The ABCSG 18 trial shows in a multicenter, randomized, double-blind, placebo-controlled, phase III trial the positive effect of denosumab, an anti-RANK ligand antibody, on bone health and delayed time to the first clinically relevant fractures. The trial showed that the time to first fracture was doubled compared with placebo. 33 The risk of bone loss and fractures is a relevant factor in all of the trials about extended endocrine therapy. The meta-analysis of the EBCTCG 8 showed that the risk of clinically relevant fractures varies in the different age groups. In the age group >55 years, a bone fracture incidence of 7.2% was registered, and this increased with age. In the >70 years group a bone loss incidence of up to 15.9% was reported. Bone-protective drugs such as bisphosphonate or denosumab should be considered additionally to prevent bone-related (severe) AEs.
There is evidence that adjuvant bisphosphonates reduce BC recurrences in bone and improve BC survival. [34] [35] [36] Patients with a low-estrogen environment at baseline of their therapy seem to benefit most. 37 A standardized bone-protective therapy in patients with long-term endocrine treatment is a daily application of calcium-cholecalciferol supplementation and should be provided for all patients, but there is evidence that calcium supplementation can increase cardiovascular events in healthy older (postmenopausal) women. Therefore, it is important to evaluate the necessity of calcium supplementation individually. A higher dietary calcium intake does not cause cardiovascular events. 38 
Genomic risk classifiers, really helpful tools?
The question arises as to how to identify patients at particular risk. Genomic testing seems to be a reliable tool for risk stratification. 27 Patients with ER + BC seem to be at higher risk for late distant recurrence than patients with ER-negative BC, which is mostly recurring within the first 5 years.
Yu and colleagues demonstrated by analyzing data of 111,993 BC patients that the hazard of BC-specific mortality in the years 0-2 (HR 3.97; 95% CI 3.66-4.30) and 2-5 (HR 1.94; 95% CI 1.85-2.05) was higher among patients with ER-negative tumors, keeping ER + as reference. However, 5-10 years after diagnosis, patients with ER + BC have an increased risk of BC-specific mortality compared with those with ER-negative BC (HR 0.71; 95% CI 0.66-0.76). 6 Wolmark and colleagues investigated the utility of the 21-Gene Recurrence Score (RS), designed to predict late (>5 years) distant recurrence in stage I and II BC, in combination with the quantitative ER expression level (ESR1). 28 RS seems to be a strong predictor for distant recurrence after 5 years in patients with high ESR1 levels. ROR is low for women with low RS. The results suggested that patients with intermediate and high RS with higher ESR1 expression levels at initial diagnosis might profit from extended adjuvant therapy. However, there are no clinical data supporting this hypothesis.
The PAM50 is another prognostic multigene test. Based on the PAM50 gene analysis, the PAM50 ROR score can be calculated and patients can be assigned to defined ROR-based risk groups.
Filipits and colleagues could demonstrate the usefulness of this test by performing the PAM50 analysis in 1246 patients of the ABCSG-8 trial. 39 Depending on their ROR score, patients were assigned to a low, intermediate or high-risk group. Between years 5 and 15, an absolute risk of distant recurrence was found of 17.5% in the highrisk and 2.4% in the low-risk group [HR 6.90 (1.89-11.87), p < 0.001], respectively. Thus, 40 the PAM50 ROR score and the ROR-based risk groups are a reliable tool to predict late distant recurrence. 41 Although it could be demonstrated that the PAM50 ROR score accurately predicted the risk of late distant recurrence, Filipits and colleagues concluded that it is still not clear whether patients in the high-risk group will benefit from extended adjuvant therapy. 42 The findings of Sestak and colleagues confirmed these results further. Follow-up data from 2137 postmenopausal women with HR + EBC from the ABCSG 8 and the TransATAC trial were analysed. It could be shown that the PAM50 ROR score added clinically important prognostic information to the clinical treatment score, which was developed on the TransATAC data set. In the follow-up years 5-10, the ROR score was significantly 43 Another multigene test is the EndoPredict (EP) with its EPclin score, which combines the EP with tumor size and nodal status. Dubsky and colleagues could demonstrate that the EP test provides significant prognostic information in the early (0-5 years) and the late (>5 years) time interval after diagnosis. A total of 1702 postmenopausal women with ER + /HER2-negative BC, who were treated with 5 years of ET and participated in the ABCSG 6 or the ABCSG 8 trial, were assigned to risk groups based on their EP score. A total of 49% of patients were stratified according to their EP score to the low-risk group. With an absolute of 1.8% of late distant metastasis at 10 years of follow up, patients in the low-risk group had a significantly improved outcome. 44 The two-gene expression ratio, HOXB13/ IL17BR (H/I) is a prognostic biomarker in ER + EBC patients. A high H/I ratio is statistically significantly associated with a reduced ROR in patients receiving extended letrozole therapy. In patients without extended letrozole therapy, a high H/I ratio identifies a subgroup that is at higher risk for late recurrence. 45 Multigene assays such as EP, PAM50 ROR score, HOXB13/IL17BR including the Breast Cancer Index seem to improve the prognostic abilities of well-established clinical predictors such as TNM stage and hormone receptor status. The identified patients at low risk for recurrence seem to have a favorable prognosis, and thus seem to have only a very little or no benefit from extended adjuvant therapy. 46 However, further investigation is required to clarify if patients at higher risk substantially benefit from adjuvant therapy beyond 5 years.
The use of biomarkers to guide decisions on adjuvant endocrine therapy in patients with earlystage BC is still a matter of debate.
There is evidence that the urokinase plasminogen activator (uPA) and its inhibitor plasminogen activator inhibitor-1 (PAI-1) can be used as predictive biomarkers in patients with HR + HER2-negative BC. 47, 48 They seem to play a major role in cancer invasion and metastasis. High levels of uPA and PAI-1 predict on the one hand poor prognosis but on the other hand benefit from adjuvant chemotherapy. 49, 50 Regarding the predictive value of microtubule associated protein (MAP)-Tau mRNA or circulating tumor cells (CTCs) 51, 52 as biomarkers, controversial results can be found. 48 Higher levels of tumor infiltrating leukocytes (TILs), for example, are associated with an increased benefit of trastuzumab in HER2 + BC. 53 Nevertheless, especially in HR + HER2-negative BC, there seems to be not enough evidence to use TILs to guide decisions on adjuvant systemic therapy. 48 What is coming next? Currently, new therapeutic targets are under investigation. Apart from HRs and HER2neu-receptor, oncogenic tyrosine kinases and related pathways, such as the PI3K/AKT/mTOR pathway, are potential targets.
Cyclin-dependent kinases play an important role in cell cycle progression. Targeting these kinases lead to a cell cycle block and might improve the outcome in aggressive BC subtypes. Based on this, CDK4/6 inhibitors seem to be promising agents and are already part of clinical phase III trials. A well-tested substance is palbociclib, either used as monotherapy or in combination with trastuzumab or cytotoxic chemotherapy. 54 Results of the currently ongoing PALLAS trial are awaited. It is a prospective, multicenter, randomized, two arm, open-label phase III study with the purpose to determine if the addition of 2 years of palbociclib to at least 5 years of standard adjuvant treatment comes along with an improved outcome in patients with HR + , HER2-negative early BC.
Another new approach is blocking the insulinelike growth factor (IGF) pathway, which is activated in 90% of BC cases and is closely related to both HER2neu-receptor and mTOR pathway. However, a single inhibition of the IGF pathway can induce a diffuse upregulation of mechanisms that potentially trigger further malignant growth progression. A promising option is a combination of IGF blockers with mTOR inhibitors, which leads to a clinical improvement and even to partial remission in metastatic BC. 55, 56 BC stem cells seem to be important mediators of therapy resistance. A new approach is to target the self-renewing signaling pathways. Agents like Delta-ligand 4-blockers are under investigation in xenograft models and show anti-BC stem cells effect. 57 The initiation process of metastatic disease might find its origin in dormant disseminated tumor cells. 58 Those cells can enter dormancy, even at a very early stage and become immune to different forms of therapy. They can develop metastatic growth 59 even after long periods of dormancy and can express, by that time, a completely different tumor biology compared with the primary tumor. 60 This might explain a lack of response to therapy even if the initially administered treatment was effective. New therapeutic strategies are aiming to either kill awoken dormant cells or keep them permanently dormant. 61 
Conclusion
Recent data demonstrate clear superiority of AI to TAM for the first 5 years as standard treatment in postmenopausal patients with HR + BC.
Taken together, there is evidence that extended adjuvant endocrine therapy has a benefit on DFS; this has been proven in several clinical trials. The initial regime, meaning if TAM or AI was administered first, must be taken into account in the decision-making process, regarding further extended ET.
To sum up, extended ET should be favored in patients who received prior treatment with TAM, especially because of the well-known fact that TAM is associated with rare but serious risk of venous thromboembolism. The extended treatment with AI after AI should be considered carefully in relation to AEs and the tumor risk profile.
Patients at higher clinical risk, such as N + with larger tumors, seem to have more benefit from extended endocrine treatment. Patients with low recurrence risk as defined by different multigenomic tools have a very good prognosis and seem to have only very limited or no additional improvement due to prolonged endocrine treatment. Extension of endocrine therapy beyond 5 years seems to be not reasonable for these patients.
However, feasible predictive markers to identify those who could probably benefit from prolonged endocrine treatment, are still unknown. The patients with clearly defined high clinical risk for recurrence (N + , large tumors etc.) should be carefully selected. The individual benefit and risk for AEs under prolonged therapy, as well as need for additional medication (for example, calciumcholecalciferol supplementation, bisphosphonates, denosumab) must be clarified.
The beneficial effect of prolonged treatment for high-risk patients, identified by using multigenomic tests, remains unclear. Thus, further studies need to be performed to confirm the advantage of extended adjuvant endocrine therapy.
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